ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Medigene Stock (ETR:MDG1) 30 days 90 days 365 days Advanced Chart Get Medigene alerts:Sign Up Key Stats Today's Range N/A50-Day Range€0.19▼€1.8652-Week Range N/AVolume63,357 shsAverage Volume306,207 shsMarket Capitalization$1.45 millionP/E RatioN/ADividend Yield1.31%Price TargetN/AConsensus RatingN/A Company OverviewMedigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More… Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address MDG1 Stock News HeadlinesPTA-Adhoc: Medigene AG: Medigene AG stellt Antrag auf Eröffnung eines InsolvenzverfahrensApril 7, 2025 | finanznachrichten.deMedigene Files Patent for Unique NK-Specific TCR Construct with European Patent OfficeMarch 13, 2025 | markets.businessinsider.com2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. April 18, 2025 | Stansberry Research (Ad)Medigene and EpimAb to develop T cell engagers for solid tumoursFebruary 28, 2025 | finance.yahoo.comPTA-News: Medigene AG: Medigene und EpimAb Biotherapeutics schließen Co-Entwicklungspartnerschaft für TCR-gesteuerte T-Zell-Engager abFebruary 27, 2025 | finanznachrichten.deMedigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell EngagersFebruary 27, 2025 | markets.businessinsider.comPTA-News: Medigene AG: Medigene AG erweitert Patentportfolio um Patenterteilung für seine JOVI Technologie in den USAFebruary 20, 2025 | finanznachrichten.deMedigene AG: Kapitalerhöhung bringt 0,25 Millionen Euro von YorkvilleFebruary 5, 2025 | finanznachrichten.deSee More Headlines MDG1 Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income$-4,667,238.14 Net Margins-249.83% Pretax MarginN/A Return on Equity-80.38% Return on Assets-27.15% Debt Debt-to-Equity Ratio12.95 Current Ratio2.39 Quick Ratio5.85 Sales & Book Value Annual Sales$1.87 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.37 Book Value€0.72 per share Price / BookN/AMiscellaneous Outstanding Shares7,619,243Free FloatN/AMarket Cap$1.45 million OptionableNot Optionable Beta0.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (ETR:MDG1) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.